Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Under Fire Over Handling Of COVID-19 Vaccine Procurement

Commission Defends Itself But Accepts Court of Auditors’ Recommendations

Executive Summary

The European Commission has come in for criticism over the way it handled the procurement of COVID-19 vaccines in the initial stages of the pandemic, particularly the lack of provisions in contracts with manufacturers regarding possible supply disruptions.

You may also be interested in...



EU Seeking Firms To Offer ‘Ever-Warm’ Production Capacity For Future Pandemics

The EU is drawing on lessons learned during the COVID-19 pandemic to set up a network of vaccine production capacities able to respond quickly to a surge in demand.

Coronavirus Notebook: EU Launches Vaccine Monitoring Scheme, AZ Vows To Defend Itself Against Legal Action

The EMA has issued updated safety advice on AstraZeneca’s COVID-19 vaccine, Vaxzevria, Valneva has decided to pursue vaccine supply deals with individual member states after a falling out with the European Commission, and Kazakhstan has begun administering the first doses of its domestically produced vaccine, QazVac.

EU Preparing Guidance On Synthetic Oligonucleotides & Peptides

Two new quality guidelines are needed to address the increase in applications for clinical trials and marketing authorizations of oligonucleotide- and peptide-based medicines, says the EU regulator.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146991

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel